SoftBank and Hanwha-backed biomanufacturer Zymergen floated at the top of its range in an upsized offering following over $870m in venture funding.
Zymergen, the US-based biomanufacturer backed by telecommunications and internet group SoftBank and conglomerate Hanwha, is going public today in a $500m initial public offering on the Nasdaq Global Select Market. The offering consists of just over 16.1 million shares, upsized from an initial allocation of 13.6 million and priced at the top of its $28…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.